Clinical trial
Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
NCT00218231 · National Institute on Drug Abuse (NIDA), NIH · Completed
Key facts
| NCT number | NCT00218231 |
|---|---|
| Title | Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia |
| Official title | Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2) |
| Lead sponsor | National Institute on Drug Abuse (NIDA), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia, Tobacco Use Disorder |
| Intervention type | Drug |
| Interventions | 300 mg/day bupropion-sr, 0 mg/day bupropion-sr |
| Enrollment | 48 |
| Start date | Jan 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Jan 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: